Das Saumya, Das M. Kumar, Anamika
Nagalakshmi S, Tejas DS, Yamini M, Taaha ZN, Monisha RL, Anumita G, Logeswaran K
Amani Jabber, Nada N. Al-Shawi, Ali F. Hasan
Nandgude TD, Parakhe PS, Patole VC
S Patel, P Soni, LK Omray
Sara A. Kadhim, Eman S. Saleh, Aymen D. Jaafar
Kamble K. G, Laddha K. S
Adeep Kujur, Sanjay J. Daharwal
Nadia M. Shalal, Affan E. Hasan, Sheelan MS. Hasan
Bhavana Akhade, Vivekanand Chatap, Prashant Jain, Mahesh Bhat
Abhinandan Patil, Firoj Tamboli, Dinanath Gaikwad, Pralhad Mudalkar, Kamal Alaskar
Krutika S. Bobde, Kanchan Upadhye, Vaibhav P. Uplanchiwar, Vinod M. Thakare, Anshu R Dudhe, Gayatri R. Katole, Namrata S. Mane, Prashant Bhokardankar
Sulaf E. Izzat, Ghassan T. Saeed
Vrushali Kharate, Mohini Kuchekar, Minal Harde, Bhushan Pimple, Vinita Patole, Manisha Salunkhe, Pooja Wadgave, Manish Bhise, Asmita Gaikwad, Harshal Tare
Sudipta Mukherjee, Biswanath SA, Jasmina Khanam, Sanmoy Karmakar, Rudranil Bhowmik
Manoj B. Shinde, Adhikrao V. Yadav
Samsul Hadi, Deni Setiawan, Kunti Nastiti, Muhammad R. Ridha, Yustinus Maladan
Valeveti SK, Pashikanti S
Amani Q. Alhadithi, Faiza Kadhim
Saraf A, Dubey N, Dubey N, Sharma M
Amit R. Bukkawar, Amit K. Jain, Vivekanand K. Chatap
Aysar A. Ali, Enass G. Sweedan
Duha A. Mohammed, Munther H. Rathi, Talib J. Kadhim
Sandhan S B, Wagh M P, Inamdar Nazma
T. Naga Varalakshmi, V. Chitra
Falguni Tandel, Aanal Pandya, Bijal Prajapati
Putri Peggy, Yanti Kosasih, Evelyn Anggie, Refi Ikhtiari
Afnan R. A. Al-Tekreeti, Khalid J. K. Luti
Tharwa H. H. Al-Tai, Hayfaa S. Al-Hadithi, Dina S. AL-Yasiry
Objective: To detected the amount of CD4 + Foxp3 + Treg cells in BD patients and to asses their correlation to disease activity.
Patients and methods: This study was applied on 60 patients with BD compared to 30 healthy group as control group from December 2020 to the end of May 2021. Their blood samples were collected to investigate blood concentrations of CD4 + marker and Foxp3 + Treg by using flow cytometer technique.
Results: The (median) of CD4 + Tcells percentage for the patient group was 10.9%, significantly higher than that of the control group 8.30% ranged (0.80–17.30). While there was a highly significant increase in the (median) 26.20% of CD4 + Foxp3 + Tcells in the patients group in comparison with the control group median (4.65%). The Treg cells determined by the proportion of CD4 + Foxp3 + in all CD4 + Tcells showed a significant increase in the (median) for patient group (10.80% ) if compared with the control group (8.50% ) (p=0.045). A significant decrease CD4 + in monocyte was detected in patient group (8.50%) in comparison to control group (12.70%)(p=0.003).
Conclusion: Patients with BD had more CD4 + , Foxp3 + Treg cells than the control group did. Monocyte levels were lower in BD patients. There was a link between disease activity and Treg concentration.
Umesh B. Telrandhe, Laxman G. Galat, Shailesha D. Chavan, Manish A. Kamble, Mahendra C. Gunde, Rajeshwar V. Khirsagar
Mohammad J. Al-Jassani, Zahraa F. Hassan, Hussein S. H. Ridha, Lamyaa Y. Radhi, Sarah A. Hamood
Mervat A. A. Al-Karkhi, Hashim K. M. Al-oubaidi
High-performance liquid chromatography (HPLC) was used to conduct quantitative and qualitative analyses of the alkaloids components and compare them to their levels in the plant. Significant variations were seen at the higher (400 mg/l) concentration of NiO NPs for boosting alkaloids molecules.
Nazar M. Abdalsahib, Lekaa K. A. Karem
Adnan A. Amer, Lekaa K. A. Karem
R. R. Tanpure, M. H. Kolhe, G. S. Shinde, R. J. Bhor
Hesham I. Kadhim, Anwer T. Obaid, Abbas M. Rahmah
Method: A total of 80 patients with acromegaly are enrolled in the study from July/2019 to April/2020. Their age range (20–72 years). They are 47 men and 33 women. Their selection was based on their visits to NDC on the basis of prescheduled appointments to be given their monthly injections of long-acting octreotide (LAR) and to be examined clinically plus conducting various types of hormonal studies and biochemical workups to assess their response to treatment on the following parameters: Adenoma size, IGF-1 and GH and its correlation with octreotide dose.
Results: It is a cross-sectional comparative clinical trial study of 80 patients with acromegaly. Mean of age was 46.7 ± 12.4 years’, and their age range (20–72 year) minimum and maximum-year-old. Mean duration of taking drug was 8 ± 6.7 years. The mean of total LRA injection was (1073.6 ± 666.2 mg). 58.75% of patients were male while 41.25% were female. 46.25% of patients do not have transsphenoidal direct surgery, but 46.25% undergo one surgery, 7.5% undergo two transsphenoidal hypophysectomies. 87.5% of patients have no gamma knife while 12.5% have gamma knife radiosurgery. Conclusion: Acromegaly is a multi systemic disease that should be diagnosed and treated as early as possible to prevent complications and improve mortality rates.
Aseel M. Aljeboree, Faraj Mohammed, Mohammed A. Jawad, Ayad F. Alkaim
Aseel M. Aljeboree, Nadher D. Radia, Zeina M. Kadam, Yahya A. Faleh,Usama S. Altimari, Ashour H. Dawood, Ayad F. Alkaim
Maha M. Ali, Wissam S. Mahmod, Afaq M. Ali
Nandgude TD, Parakhe PS, Mishra RK
Sahil Goel, Ankita Thakur, Pallavi Bassi, Parveen Kumar, Arindam Chatterjee, Omprakash Sharma
Manish Kushwah, Avijit Mazumder, Richa Shakya
Swati Pund, Vaibhav Changediya, Vikas Rajurkar
Ritchu Babbar, Swikriti, Sandeep Arora, Thakur G. Singh
Chauhan V.S., Mazumder Avijit, Chandel Shobhini
Aishwaray, Saumya Das, Ananya Pandey, Gajender